Praxis Precision Medicines, Inc. PRAX Ulixacaltamide — Program-specific expenses

Other product segments

Similar metrics at other companies

HGVMarketing expense — Expenses

$239M+3.9%

HGVRental expense — Expenses

$204M+4.6%

HGVSelling expense — Expenses

$181M-7.2%

HGVClub expense — Expenses

$22M+10.0%

HGVLicense fee expense — Expenses

$53M+8.2%

HGVProperty management expense — Expenses

$37M+8.8%

FAQ

What is Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses?

Praxis Precision Medicines, Inc. (PRAX) reported ulixacaltamide — program-specific expenses of $13.3M in Q2 2026.

How has Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses changed year-over-year?

Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses decreased by 27.7% year-over-year, from $18.39M to $13.3M.

What is the long-term trend for Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses?

Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s ulixacaltamide — program-specific expenses has grown at a 80.2% compound annual growth rate (CAGR), from $19.46M to $63.21M.

What does ulixacaltamide — program-specific expenses mean?

This metric represents the aggregate direct costs associated with the research, development, and commercialization activities specifically attributable to the Ulixacaltamide program. It captures the financial resources deployed to advance this clinical-stage asset through its regulatory and operational lifecycle. Monitoring these expenses provides insight into the capital intensity and investment priority assigned to this specific therapeutic candidate within the broader pipeline.